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Abstract. Pulmonary synovial sarcoma is a rare but aggres-
sive disease. The present study describes the case of a 
68-year-old female with pulmonary synovial sarcoma. The 
patient was mistakenly treated for small cell lung cancer due to 
false-positive staining for synaptophysin and cluster of differ-
entiation 56. Despite severe myelotoxicity, platinum-containing 
chemotherapies (cisplatin plus irinotecan and carboplatin plus 
etoposide) were not effective. As a third-line therapy, the 
patient received amrubicin (AMR) monotherapy. A partial 
response was achieved, and the patient was able to undertake 
ordinary daily life at home for 13 months from the initiation 
of AMR chemotherapy. Due to the atypical clinical condition 
and unusual response to chemotherapy in this patient, the 
pathological examination was repeated. The SS18 split-signal 
was detected in fluorescence in situ hybridization analysis. 
From these results, the tumor was diagnosed as a monophasic 
synovial sarcoma. To the best of our knowledge, this is the 
first case of a patient with pulmonary synovial sarcoma who 
underwent successful treatment with AMR. The present case 
could demonstrate a specific chemosensitivity of such a rare 
tumor.
Introduction
Although rare, primary synovial sarcoma is one of the most 
common variants of pulmonary sarcoma. Primary synovial 
sarcoma usually derive from soft tissue, most commonly in 
young individuals (1). Diagnosis requires a tissue sample in the 
form of a needle or open biopsy. Surgical resection is the stan-
dard primary treatment, and a 5-year distant metastasis-free 
survival of >60% may be achievable (2,3). However, recur-
rence remains a major problem and is responsible for treatment 
failures (4). Clinically, pulmonary synovial sarcoma may be 
characterized as an aggressive tumor; to the best of our knowl-
edge, there has not been a single report of a long-term follow-up 
of a patient with pulmonary synovial sarcoma. The present 
study describes the case of a patient with recurrent pulmonary 
synovial sarcoma, who was effectively treated with amrubicin 
(AMR) monotherapy as a third-line chemotherapy following 
cisplatin and irinotecan and carboplatin and etoposide.
Case report
A 68-year-old female was admitted to hospital with a cough, 
dyspnea on exertion and a large, right-sided pleural effusion. 
The patient was a non-smoking housewife with no history of 
asbestos exposure. Thirty‑five months prior to this admission, 
the patient underwent a left upper lobectomy and mediastinal 
lymph node dissection for a mass in the left upper lobe of 
the lung. The pathological diagnosis of the resected tumor 
was small cell lung cancer (SCLC) due to its weakly posi-
tive staining for synaptophysin and cluster of differentiation 
(CD) 56. Following the surgery, the patient received three 
courses of chemotherapy with cisplatin and irinotecan; 
however, local recurrence developed at the left mediastinum. 
The patient was therefore referred to the Mito Medical Center 
(Mito, Japan) to receive further chemotherapy. Chest computed 
tomography (CT) revealed a large mass in the left mediastinum; 
the mediastinum was shifted to the right and large, left-sided 
pericardial and pleural effusions were observed (Fig. 1). 
The patient then received two courses of chemotherapy with 
carboplatin and etoposide, but the response was evaluated as a 
progressive disease, despite severe myelosuppression (grade 4 
thrombocytopenia in the National Cancer Institute-Common 
Toxicity Criteria), which required platelet transfusion. The 
patient additionally developed cardiac tamponade, which was 
successfully treated with tube drainage. Informed consent was 
obtained from the patient's family.
As a third-line chemotherapy, to avoid severe myelosuppres-
sion, weekly AMR monotherapy was selected: Administration 
of 35 mg/m2 AMR three times during a four-week period (5). 
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Myelotoxicity could then be evaluated prior to the next AMR 
administration. A partial response was achieved (Fig. 2) with 
no severe myelotoxicity. The patient received eight courses of 
the chemotherapy and was able to undertake ordinary daily 
life at home for 13 months from the initiation of the AMR 
chemotherapy. Local recurrence at the left mediastinum then 
developed and the patient succumbed of the disease, 50 months 
after the initial surgical resection of the tumor.
Due to the atypical clinical condition and unusual response 
to chemotherapy in this patient, the pathological examination 
was repeated. The resected tumor was composed of spindle 
cells with increased nuclear chromatin arranged uniformly 
(Fig. 3). Immunostaining with synaptophysin and CD56 
revealed negative results. The tumor cells were positive for 
vimentin and B-cell lymphoma 2, but negative for cytokeratin 
AE1/AE3, α-smooth muscle actin, desmin, S-100, CD34, 
chromogranin A and synaptophysin. The SS18 split-signal 
was detected in fluorescence in situ hybridization analysis. 
From these results, the tumor was diagnosed as a monophasic 
synovial sarcoma.
Discussion
Pulmonary synovial sarcoma is a rare, aggressive primary 
tumor. The neoplasm was first described in 1995 by 
Zeren et al (6) as a distinctive pulmonary tumor of the lung, 
sharing histological and immunohistochemical characteristics 
with the monophasic synovial sarcoma of the soft tissue. 
Chest pain, dyspnea, cough and hemoptysis are the most 
common symptoms in patients with pulmonary synovial 
sarcoma (7); however, certain patients do not present with any 
symptoms (8). Radiologically, pulmonary synovial sarcoma 
appears mostly as well-circumscribed nodules of considerable 
size (9). In order to diagnose pulmonary synovial sarcoma, it is 
mandatory to exclude extrathoracic primary synovial sarcoma 
by whole-body survey. Detection of the t(X;18) chromosomal 
translocation can confirm the diagnosis (10,11). In the patient in 
the present case, no primary site other than the lung was found 
and positive split-signals from an SS18 probe were detected; a 
diagnosis of synovial sarcoma was thus confirmed. The patient 
was misdiagnosed with SCLC due to weakly positive staining 
for synaptophysin and CD56. SCLC is a tumor arising in a 
Figure 1. Chest computed tomography revealed (A) a large mass in the left mediastinum, with the mediastinum shifted to the right; and (B) pericardial and 
pleural effusion.
Figure 2. Chest computed tomography following two courses of chemotherapy showed (A) a partial response and (B) disappearance of the pericardial fluid.
Figure 3. Pathological examination using the resected tumor, which was 
composed of spindle cells with increased nuclear chromatin arranged uni-
formly: (A) Low‑power field (x100) and (B) high‑power field (x200), stained 
with hematoxylin-eosin. 
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relatively large bronchus and predominantly occurs in patients 
with a smoking habit. In Japan, the majority of patients with 
SCLC have been males with a history of smoking (12). The 
present case was a female patient without a smoking habit. 
In addition, the patient had no history of exposure to carci-
nogenic chemicals such as asbestos. The poor response to 
platinum-containing chemotherapy was also unusual. The 
SCLC in this patient was therefore somewhat different from 
that usually observed. The histopathology of the resected 
tumor was re-evaluated and a correct diagnosis was achieved.
Surgical removal of the resectable tumor is the choice of 
treatment for pulmonary synovial sarcoma, and the prognosis 
of the disease is poor if the complete surgical resection cannot 
be performed. Bacha et al (13) reported that successful complete 
resection was significantly associated with increased survival, 
and that the size and grade of the tumors were not. As there have 
been no randomized control trials, the role of chemotherapy for 
unresectable and recurrent tumors remains unclear.
AMR is an anthracycline derivative with a structure similar 
to that of doxorubicine (14). Anthracyclines are widely used 
in the treatment of a variety of sarcomas (15). Although the 
cumulative dose-limiting cardiotoxicity is a major obstacle to 
its use (16), AMR has shown considerably less cardiotoxicity 
than doxorubicin in experimental models (17,18) and clinical 
trials (19,20). AMR has been demonstrated to be effective 
for previously treated SCLC (21,22). In the clinical course of 
the present case, the patient developed myelotoxicity, which 
required a platelet transfusion subsequent to the second course 
of the second-line chemotherapy with carboplatin and etopo-
side. AMR was therefore administered weekly (three times in 
four weeks at 35 mg/m2), taking the severe myelotoxicity of 
the second-line chemotherapy into consideration.
To the best of our knowledge, this is the first case of a 
patient with pulmonary synovial sarcoma to be effectively 
treated with AMR. Following AMR administration, the tumor 
exhibited a decrease in size on serial chest CT scan, and the 
survival benefit was obtained without any severe myelotoxicity 
and cardiotoxicity, although the patient had a history of cardiac 
tamponade. The present case could demonstrate a specific 
chemosensitivity of such a rare tumor.
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